Considering the Promises of Point-of-Care Manufacturing.

The article focuses on the emergence of advanced manufacturing technology in the biopharmaceutical industry, indicating a shift toward distributed manufacturing models. Topics discussed include the U.S. Food and Drug Administration's recognition of the need for flexible manufacturing, regulatory challenges, and the potential of point-of-care (POC) manufacturing to address issues such as drug shortages and pandemic preparedness.